Specialists in quantifying the current and future burden of non-communicable and rare genetic diseases.
Our data-driven epidemiology generates evidence to support strategic planning and portfolio management at each stage of the drug development process, helping to bring new therapies to patients faster.
From molecule to market, our solutions can help.
Deep expertise in disease epidemiology combined with entrepreneurial vision. Our work has been widely published and peer-reviewed by world-leading experts.
Why Us?We’ve spent over a decade developing our methodology to help you ask the right questions and make the best decisions.
SolutionsWe’ve answered all kinds of questions for many different organisations, covering over 25 NCDs and rare genetic diseases in over 80 countries.
Track RecordOur experienced and multidisciplinary team brings together epidemiologists, geneticists, mathematicians, data scientists, researchers, and software engineers.
About UsThe Movember Institute of Men’s Health has just released a new report, “The Real Face of Men’s Health”, examining the state of men’s health in Canada,
In 2023, five conditions – coronary heart disease (CHD), colorectal cancer, lung cancer, chronic obstructive pulmonary disease (COPD), and suicide – were responsible for the greatest number of years of life lost to ill health among Canadian men.
HealthLumen was commissioned to carry out the health economic modelling for this report. Our modelling showed that if all preventable cases of these five conditions had been avoided in men in 2023, Canada could have saved $12.4 billion CAD.
ReadChronic Kidney Disease (CKD) affects more than 10% of the population worldwide and is often associated with other conditions such as diabetes and hypertension. However, rare kidney diseases, although individually rare, collectively exert a notable impact on kidney health – accounting for an estimated 5–10% of CKD cases.
Despite their impact, rare kidney diseases often remain underdiagnosed and under-recognised within CKD care and policy frameworks. This raises critical questions: Why do so many rare kidney conditions go undiagnosed? Could rare kidney diseases account for more CKD cases than previously thought? And what would earlier diagnosis and targeted intervention mean for patients, health systems, and payers? This article aims to address these questions.
ReadOne of the main challenges faced by all companies conducting strategic planning for rare diseases is obtaining accurate data on the size of these often complex patient populations. The challenge of accurately estimating the prevalence of rare diseases is illustrated in the literature, where prevalence figures often span strikingly wide ranges – sometimes varying by orders of magnitude between studies. This level of uncertainty affects every step of the molecule-to-market planning cycle. The growing availability of large-scale genetic databases offers a solution to close the gap on wide ranging rare disease prevalence estimates, and can complement the data derived from other sources including the literature and information gathered from clinical practice.
ReadChronic kidney disease (CKD) is a major global health issue – affecting an estimated 1 in 10 people – yet it is frequently overlooked on health agendas worldwide. In its early stages, CKD is often asymptomatic, and many individuals are unaware that they have CKD until the disease has progressed to later stages, where it becomes harder and more costly to treat – with patients facing the prospect of dialysis or kidney transplant. This makes early CKD detection critical to improving patient outcomes and reducing the growing health and economic burden of CKD worldwide. Recognising this, the World Kidney Day campaign this year is centred around the theme: “Detect early, protect kidney health.”
Read